Ponatinib in refractory Philadelphia chromosome-positive leukemias.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  New England Journal of Medicine

• Publication date

  2012-11-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1205127PMID 23190221PMCID PMC3777383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576

  2013cited by this paper
• Abstract 853: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1

  2012cited by this paper
• Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

  2012cited by this paper
• Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

  2012cited by this paper
• Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

  2011cited by this paper
• Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

  2011cited by this paper
• Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

  2011cited by this paper
• Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies.

  2011cited by this paper
• Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

  2011cited by this paper
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

  2010cited by this paper
• Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

  2010cited by this paper
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

  2010cited by this paper
• Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  2010cited by this paper
• Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

  2010cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

  2009cited by this paper
• NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

  2009cited by this paper
• Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

  2009cited by this paper
• Treatment selection after imatinib resistance in chronic myeloid leukemia

  2009cited by this paper
• The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.

  2009cited by this paper
• molecule Beyond the increasing complexity of the immunomodulatory HLA-G

  2008cited by this paper
• Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

  2008cited by this paper
• Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.

  2008cited by this paper
• Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.

  2008cited by this paper
• Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.

  2008cited by this paper
• Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

  2007cited by this paper
• Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

  2007cited by this paper
• Drug development in oncology: classical cytotoxics and molecularly targeted agents.

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

  2006cited by this paper
• International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

  2006cited by this paper
• Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

  2006cited by this paper
• The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

  2005cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• FLT3: ITDoes matter in leukemia

  2003cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  2000cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper
• Clinical Trials and Observations

  1996cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990influential reference
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper

• Evolving Therapeutic Algorithms in Chronic Myeloid Leukemia: Integrating Efficacy, Safety, and Survivorship.

  2026cites this paper
• Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia

  2025cites this paper
• Bridging the Gap Between hiPSC-CMs Cardiotoxicity Assessment and Clinical LVEF Decline Risk: A Case Study of 21 Tyrosine Kinase Inhibitors

  2025cites this paper
• Mini-hyper CVD-inotuzumab with asciminib as salvage therapy for ponatinib-refractory Ph + B-ALL and CML lymphoid blast crisis

  2025cites this paper
• BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d’Ivoire

  2025cites this paper
• KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT3+ blast phase chronic myeloid leukemia

  2025cites this paper
• Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia

  2025cites this paper
• Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?

  2025cites this paper
• Exploring critical hub genes and potential drug candidates for PCOS: A systems biology approach.

  2025cites this paper
• Towards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs

  2025cites this paper
• Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation

  2025cites this paper
• Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1.

  2025cites this paper
• Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.

  2025cites this paper
• Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors

  2025cites this paper
• Ponatinib may make allogeneic hematopoietic stem cell transplantation unnecessary for CML-BC under specific conditions, such as de novo cases: a case series of de novo CML-BC treated with ponatinib and no transplantation

  2025cites this paper
• Phase 2 trial of ponatinib in patients with metastatic gastrointestinal stromal tumor following failure or intolerance of prior therapy with imatinib (POETIG trial).

  2025cites this paper
• Practical Bayesian Guidelines for Small Randomized Oncology Trials

  2025cites this paper
• Integral approach to organelle profiling in human iPSC-derived cardiomyocytes enhances in vitro cardiac safety classification of known cardiotoxic compounds

  2025cites this paper
• A case of pityriasis rubra pilaris secondary to ponatinib

  2025cites this paper
• Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient

  2025cites this paper
• Population Pharmacokinetic and Exposure–Response Analyses for Ponatinib in the Phase 3 PhALLCON Study

  2025cites this paper
• Comprehensive Risdiplam Synthesis Overview: From Cross-Coupling Reliance to Complete Palladium Independence

  2025cites this paper
• Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent

  2025cites this paper
• Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis

  2025cites this paper
• Off-label use of anlotinib in malignancies’ treatment: efficacy and management of adverse reactions

  2025cites this paper
• A prospective study evaluating the safety and pharmacokinetics of ponatinib at a fixed dose in six paediatric patients with philadelphia chromosome‐positive leukaemia: JCCG PedPona19 study

  2025cites this paper
• Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors

  2025cites this paper
• CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5‐BLTR Signaling Pathway

  2025cites this paper
• The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair

  2025cites this paper
• Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

  2024cites this paper
• New latency-promoting agents for a block-and-lock functional cure strategy

  2024cites this paper
• Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study

  2024cites this paper
• Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.

  2024cites this paper
• Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.

  2024cites this paper
• Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis

  2024cites this paper
• Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.

  2024cites this paper
• Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia.

  2024cites this paper
• Targeting SARS-CoV-2-Induced Cardiovascular Injury: Exploring the Potential of Ponatinib in Mitigating Cardiovascular Necroptosis in COVID-19.

  2024cites this paper
• Autoimmune complications of tyrosine kinase inhibitors in cancer therapy: Clinical insights, mechanisms, and future perspectives

  2024cites this paper
• Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison

  2024cites this paper
• Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia

  2024cites this paper
• Sensitivity to Tyrosine Kinase Inhibitors in a Human Philadelphia Chromosome-Positive (Ph+) Leukemia Model With the T315I-Inclusive Compound Mutation

  2024cites this paper
• Ponatinib and prednisolone induce sustained remission in a relapsed case of mixed-phenotype acute leukemia with BCR::ABL1 fusion intolerant to dasatinib

  2024cites this paper
• Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1-positive acute lymphoblastic leukemia.

  2024cites this paper
• Computational Biophysical Characterization of the Effect of Gatekeeper Mutations on the Binding of Ponatinib to the FGFR Kinase.

  2024cites this paper
• Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia

  2024cites this paper
• Ponatinib‐review of historical development, current status, and future research

  2024cites this paper
• Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase

  2024cites this paper
• Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells

  2024cites this paper
• ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells

  2024cites this paper
• Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.

  2024cites this paper
• Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel.

  2024cites this paper
• Potential protein kinase inhibitors that target G-quadruplex DNA structures in the human telomeric regions

  2024cites this paper
• The molecular signature of BCR::ABLP210 and BCR::ABLT315I in a Drosophila melanogaster chronic myeloid leukemia model

  2024cites this paper
• Arterio-Occlusive Events Among Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors.

  2024cites this paper
• Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.

  2024cites this paper
• Investigation of the Role of NLRP3 Inflammasome Activation in New-Generation BCR-ABL1 Tyrosine Kinase Inhibitors-Induced Hepatotoxicity.

  2024cites this paper
• Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing

  2023cites this paper
• Ponatinib-Induced Pneumonitis with Severe Acute Respiratory Distress Syndrome

  2023cites this paper
• Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis

  2023cites this paper
• Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors

  2023cites this paper
• Результаты применения асциминиба, первого аллостерического ингибитора BCR::ABL1-тирозинкиназы, у больных хроническим миелолейкозом со множественной резистентностью к предшествующей терапии

  2023cites this paper
• Avanços Terapêuticos de Última Geração para Cânceres Hematológicos: Leucemia, Linfoma e Mieloma

  2023cites this paper
• Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.

  2023cites this paper
• Ponatinib: An update on its drug targets, therapeutic potential and safety.

  2023cites this paper
• Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis.

  2023cites this paper
• BALF metagenomic next-generation sequencing analysis in hematological malignancy patients with suspected pulmonary infection: clinical significance of negative results

  2023cites this paper
• Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A

  2023cites this paper
• Management of chronic myeloid leukemia in 2023 – common ground and common sense

  2023cites this paper
• Ponatinib Represses Latent HIV-1 by Inhibiting AKT-mTOR

  2023cites this paper
• Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review

  2023influential citation
• Whole exome and transcriptome analysis revealed the activation of ERK and Akt signaling pathway in canine histiocytic sarcoma

  2023cites this paper
• Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database

  2023cites this paper
• Novel clinical trial designs with dose optimization to improve long-term outcomes.

  2023cites this paper
• BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia.

  2023cites this paper
• Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia

  2023cites this paper
• Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update

  2023cites this paper
• LC-HRMS and NMR studies for characterization of forced degradation impurities of ponatinib, a tyrosine kinase inhibitor, insights into in-silico degradation and toxicity profiles.

  2023cites this paper
• Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib

  2023cites this paper
• I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition

  2023cites this paper
• Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia

  2023cites this paper
• PTEN‐AKT pathway attenuates apoptosis and adverse remodeling in ponatinib‐induced skeletal muscle toxicity following BMP‐7 treatment

  2023cites this paper
• Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

  2022cites this paper
• University of Birmingham Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT)

  2022cites this paper
• Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review

  2022cites this paper
• Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review

  2022cites this paper
• Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

  2022cites this paper
• Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

  2022cites this paper
• Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis

  2022cites this paper
• Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia

  2022cites this paper
• Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

  2022cites this paper
• Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.

  2022cites this paper
• Philadelphia chromosome-positive acute lymphoblastic leukemia carrying the p230 μ-BCR-ABL1 fusion gene

  2022cites this paper
• Immune-related adverse events of cancer immunotherapies targeting kinases.

  2022cites this paper
• Small molecule inhibitors targeting the cancers

  2022cites this paper
• Management of chronic myeloid leukaemia patients treated with ponatinib in a real‐life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA)

  2022cites this paper
• Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies

  2022cites this paper
• Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review.

  2022cites this paper
• Targeting mutations in cancer

  2022cites this paper
• BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

  2022influential citation